NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Polo-like kinase 1 (PLK1) is a serine/threonine protein kinase considered to be the master player of cell-cycle regulation during mitosis. It is indeed involved in centrosome maturation, bipolar spindle formation, chromosome separation, and cytokinesis. PLK1 is overexpressed in a variety of human tumors and its overexpression often correlates with poor prognosis. Although five different PLKs are described in humans, depletion or inhibition of kinase activity of PLK1 is sufficient to induce cell-cycle arrest and apoptosis in cancer cell lines and in xenograft tumor models. NMS-P937 is a novel, orally available PLK1-specific inhibitor. The compound shows high potency in proliferation assays having low nanomolar activity on a large number of cell lines, both from solid and hematologic tumors. NMS-P937 potently causes a mitotic cell-cycle arrest followed by apoptosis in cancer cell lines and inhibits xenograft tumor growth with clear PLK1-related mechanism of action at well-tolerated doses in mice after oral administration. In addition, NMS-P937 shows potential for combination in clinical settings with approved cytotoxic drugs, causing tumor regression in HT29 human colon adenocarcinoma xenografts upon combination with irinotecan and prolonged survival of animals in a disseminated model of acute myelogenous leukemia in combination with cytarabine. NMS-P937, with its favorable pharmacologic parameters, good oral bioavailability in rodent and nonrodent species, and proven antitumor activity in different preclinical models using a variety of dosing regimens, potentially provides a high degree of flexibility in dosing schedules and warrants investigation in clinical settings. Mol Cancer Ther; 11(4); 1006–16. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Lens, S. M. A., Voest, E. E., & Medema, R. H. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2964 · Cited by 597 · cited 1×
“intense efforts to identify and develop small-molecule inhibitors of PLK1 and indeed different compounds are currently under clinical investigation (19).”
Background
Cited by
Present and Future Perspective on PLK1 Inhibition in Cancer Treatment
Chiappa, M., Petrella, S., Damia, G., Broggini, M., Guffanti, F., & Ricci, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903016 · Cited by 120
Ahn, D. H., Barzi, A., Ridinger, M., Samuëlsz, E., Subramanian, R. A., Wu, C.-C., Croucher, P. J. P., Smeal, T., Kabbinavar, F. F., & Lenz, H.-J. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3053 · Cited by 49
“Onvansertib is ahighlypotent,reversible, andselectivePLK1 kinase inhibitor, inducing mitotic arrest and ultimately apoptosis in cancer cells (21).”
Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers
Pandey, D., Chauhan, S. C., Kashyap, V. K., & Roy, K. K. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116771 · Cited by 32
Therapeutic Targets of KRAS in Colorectal Cancer
Rahman, S., Garrel, S., Gerber, M., Maitra, R., & Goel, S. (2021) · Cancers · doi:10.3390/cancers13246233 · Cited by 28
“One such drug is Onvansertib, which is a selective competitive inhibitor PLK-1 inhibitor [42].”
Background
Metadata
- Authors
- Valsasina, B., Beria, I., Alli, C., Alzani, R., Avanzi, N., Ballinari, D., Cappella, P., Caruso, M., Casolaro, A., Ciavolella, A., Cucchi, U., De Ponti, A., Felder, E., Fiorentini, F., Galvani, A., Gianellini, L. M., Giorgini, M. L., Isacchi, A., Lansen, J., Pesenti, E., Rizzi, S., Rocchetti, M., Sola, F., & Moll, J.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2012-04-01
- Volume
- 11
- Issue
- 4
- Pages
- 1006-1016
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2116068077
- Cited by
- 123
- References
- 2
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies. https://app.cochat.ai/papers/10.1158/1535-7163.mct-11-0765
- The paper
- Valsasina, B., Beria, I., Alli, C., Alzani, R., Avanzi, N., Ballinari, D., Cappella, P., Caruso, M., Casolaro, A., Ciavolella, A., Cucchi, U., De Ponti, A., Felder, E., Fiorentini, F., Galvani, A., Gianellini, L. M., Giorgini, M. L., Isacchi, A., Lansen, J., . . . Moll, J. (2012). NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-11-0765
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.